Survival signals and targets for therapy in breast implant-associated ALK- anaplastic large cell lymphoma

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4549-4559

  Lechner, Melissa G ^a   Megiel, Carolina ^a   Church, Connor H ^a   Angell, Trevor E ^a   Russell, Sarah M ^a   Sevell, Rikki B ^a   Jang, Julie K ^a   Brody, Garry S ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANAPLASTIC LYMPHOMA KINASE; B7 ANTIGEN; CD2 ANTIGEN; CD30 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 6 RECEPTOR; MICROSOMAL AMINOPEPTIDASE; NOTCH1 RECEPTOR; PREDNISONE; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ANTIGEN PRESENTATION; ARTICLE; BREAST BIOPSY; BREAST ENDOPROSTHESIS; BREAST IMPLANT ASSOCIATED T CELL ANAPLASTIC LYMPHOMA; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE; CELL SURVIVAL; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPE; LARGE CELL LYMPHOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROMA; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST IMPLANTATION; FEMALE; HUMANS; INTERLEUKIN-6; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MOLECULAR TARGETED THERAPY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84865737474     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0101     Document Type: Article

References (48)

1. Lechner MG, Lade S, Liebertz DJ, Prince HM, Brody GS, Webster HR, et al. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer 2011;117:1478-89.
2. Lazzeri D, Agostini T, Bocci G, Giannotti G, Fanelli G, Naccarato AG, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer 2011;11: 283-96.
3. Carty MJ, Pribaz JJ, Antin JH, Volpicelli ER, Toomey CE, Farkash EA, et al. A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg 2011;128: 112e-118e.
4. Popplewell L, Thomas SH, Huang Q, Chang KL, Forman SJ. Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma 2011;52:1481-7.
5. Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol 2008;21:455-63.
6. Kim B, Roth C, Chung KC, Young VL, van Busum K, Schnyer C, et al. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg 2011;127:2141-50.
7. Wong AK, Lopategui J, Clancy S, Kulber D, Bose S. Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature. Am J Surg Pathol 2008;32:1265-8.
8. Newman MK, Zemmel NJ, Bandak AZ, Kaplan BJ. Primary breast lymphoma in a patient with silicone breast implants: a case report and review of the literature. J Plast Reconstr Aesthet Surg 2008; 61:822-5.
9. Sahoo S, Rosen PP, Feddersen RM, Viswanatha DS, Clark DA, Chadburn A. Anaplastic large cell lymphoma arising in a silicone breast implant capsule: a case report and review of the literature. Arch Pathol Lab Med 2003;127:e115-8.
10. Lipworth L, Tarone RE, McLaughlin JK. Breast implants and lymphoma risk: a review of the epidemiologic evidence through 2008. Plast Reconstr Surg 2009;123:790-3.
11. Gaudet G, Friedberg JW, Weng A, Pinkus GS, Freedman AS. Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma 2002;43:115-9.
12. Brody GS, Deapen D, Gill P, Epstein A, Martin S, Elatra W. T cell non- Hodgkin's anaplastic lymphoma associated with one style of breast implants [abstract]. In: Proceedings of the 89th Annual Conference of the American Society of Plastic Surgeons; 2009 Mar 20-23; Seattle, WA. Beverly (MA): AAPS; 2009. Abstract nr 42.
13. Stein H, Foss H-D, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95.
14. Bishara MR, Ross C, Sur M. Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentation. Diagn Pathol 2009;4:11.
15. de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbé E, Casparie MK, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008;300:2030-5.
16. Kempf W. CD30+ Lymphoproliferative Disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006;33 Suppl 1:58-70.
17. Rosen ST, Querfeld C. Primary cutaneous T-cell Lymphomas. Hematology Am Soc Hematol Educ Program 2006;323-30.
18. Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica 2009;94:897-900.
19. Fritzsche FR, Pahl S, Petersen I, Burkhardt M, Dankof A, Dietel M, et al. Anaplastic large-cell non-Hodgkin's lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer - a case report. Virchows Arch 2006;449:561-4.
20. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
21. Lamant L, Espinos E, Duplantier M, Dastugue N, Robert A, Allouche M, et al. Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a 'small-cell variant' of ALCL. Leukemia 2004;18:1693-8.
22. Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry.AmJClin Pathol 2003;119:205-12.
23. Herbst H, Drexler HG. CD30-positive anaplastic large cell lymphoma cell lines. In:Masters JRW, Palsson BO, editors. Human cell culture: cancer cell lines. Part 3. Leukemias and lymphomas. Vol. 3. Netherlands: Springer; 2000. p. 355-70.
24. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T, et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011;9:90.
25. Thériault C, Galoin S, Valmary S, Selves J, Lamant L, Roda D, et al.PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases. Mod Pathol 2000;13:1269-79.
26. Venard V, Carret AS, Pascal N, Rihn B, Bordigoni P, Le Faou A. A convenient semi-quantitative method for the diagnosis of Epstein-Barr virus reactivation. Arch Virol 2000;145:2211-6.
27. Pawson R, Schulz TF, Matutes E, Catovsky D. The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997; 11:1305-11.
28. Drexler HG. Anaplastic large cell lymphoma cell lines. In: The leukemia-lymphoma cell line facts book. San Diego, CA: Academic Press; 2001. p. 487-503.
29. + and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003;9:3692-9.
30. Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003;22:5399-407.
31. Schlette E, Medeiros LJ, Goy A, Lai R, Rassidakis G. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-8.
32. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010;115:1026-36.
33. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q, et al. Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 2006;20:1602-9.
34. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-47.
35. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK +anaplastic large-cell lymphoma. Blood 2006;108:2796-803.
36. Kwon MJ, Choi YL, Sung KW, Kang SY, Park SM, Choi SY, et al. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors. Pathol Res Pract 2011;207: 634-9.
37. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000;157:1137-46.
38. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99:3398-403.
39. Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008; 280-8.
40. Merkel O, Hamacher F, Sifft E, Kenner L, Greil R; European Research Initiative on Anaplastic Large Cell Lymphoma. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 2011;10:1127-36.
41. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007;26:373-400.
42. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011;71:3182-8.
43. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kB pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008;111:3701-13.
44. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008;13:7-9.
45. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-84.
46. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011;30: 125-40.
47. Yamada G, Kitamura Y, Sonoda H, Harada H, Taki S, Mulligan RC, et al. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 1987;6: 2705-9.
48. Hassuneh MR, Nagarkatti PS, Nagarkatti M. Evidence for the participation of interleukin-2 (IL-2) and IL-4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin. Blood 1997;89:610-20.